{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:24:59Z","timestamp":1747185899703,"version":"3.40.5"},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Currently, the response of cutaneous melanoma metastases (CMM) to treatment with Talimogene Laherparepvec (T\u2010VEC) is evaluated by clinical examination, macroscopic lesion photography and 3\u2010monthly PET\u2010CT scans. When a complete response (CR) is suspected, biopsies are taken for histopathological confirmation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We set out to investigate the feasibility of dermoscopy in monitoring the response to T\u2010VEC in a pilot study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six patients with CMM treated with T\u2010VEC monotherapy were enrolled in the pilot study. Patients were treated with T\u2010VEC according to protocol, and the response was monitored with clinical examination, macroscopic lesion photography and 3\u2010monthly PET\u2010CT scans. For this study, 1\u20133 cutaneous metastases per patient were selected. Macroscopic and dermoscopic pictures of these metastases were taken at baseline, prior to each treatment with T\u2010VEC and prior to histological biopsy. The pictures were evaluated by two investigators, using a colour\u2010based pattern classification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 11 CMM were dermoscopically assessed, 93% was located on the extremities. Four metastases had a blue pattern, two metastases had a pink pattern, three metastases had a brown pattern, and two metastases had mixed patterns. Metastases with a pink pattern harboured glomerular and arborizing vessels that diminished and vanished during treatment T\u2010VEC, indicating CR. The remaining metastases did not show changes on a dermoscopic level that were not also seen on macroscopic level. Five patients achieved CR to T\u2010VEC, one patient is still on treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results suggest that for CMM with a pink pattern, dermoscopy can provide additional information regarding the response to T\u2010VEC. For cutaneous metastases with a blue, brown or a mixed patterns, dermoscopy did not provide additional information on top of the information obtained through physical examination and lesion photography. More studies would be needed to determine the exact role of dermoscopy in the evaluation of CMM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18479","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T14:28:56Z","timestamp":1659536936000},"page":"2373-2378","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-289X","authenticated-orcid":false,"given":"E.H.A.","family":"Stahlie","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek (NKI\u2010AVL)  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.J.","family":"van Akkooi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek (NKI\u2010AVL)  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Plasmeijer","sequence":"additional","affiliation":[{"name":"Department of Dermatology Netherlands Cancer Institute \u2013 Antoni van Leeuwenhoek (NKI\u2010AVL)  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0158-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02839-7"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11111-w"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10868.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0302a11"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12749"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.05.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.38"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200410000-00006"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14926"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12314"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S133699"},{"volume-title":"Imlygic (talimogene laherperepvec) Suspension for Intralesional Injection: US Prescribing Information","year":"2015","author":"Amgn","key":"e_1_2_7_16_1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199903000-00005"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00811.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:10:32Z","timestamp":1692634232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/jdv.18479"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18479","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"2022-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}